Dublin, May 23, 2023 (GLOBE NEWSWIRE) -- The "Companion Diagnostics: Technologies and Markets" report has been added to ResearchAndMarkets.com's offering.
The global market for companion diagnostics was valued at $5.5 billion in 2021. The market is forecast to grow from $6.4 billion in 2022 at a compound annual growth rate (CAGR) of 15.3% to reach about $13.0 billion by the end of 2027.
The current report provides detailed coverage of the companion diagnostics market. This report highlights the current and future market potential of companion diagnostics, and it includes a detailed analysis of the drivers, opportunities, restraints and challenges in the market.
Precision medicine or personalized medicine is the future of healthcare. PM is currently the most advanced in oncology, but it has broader applications beyond oncology in fields such as neurology and cardiovascular diseases. Companion diagnostics (CDx) has emerged with the advent of personalized medicine.
Companion diagnostics is developed parallel to a new drug via the drug-diagnostic co-development model. The field has expanded from a few oncology drugs with companion diagnostics to involve multiple therapeutic areas, and the number of combinations has increased substantially over the years. The rapidly surging interest of the medical community and pharmaceutical companies in personalized medicine will create demand for companion diagnostics.
This report will provide a detailed analysis of the key factors governing the growth of the companion diagnostics industry, including strategic insights and recommendations for those players looking to expand their markets.
The report also features market projections to 2027 and market ranking for key market players. It also covers the competitive environment and regulatory scenario. The report details the companion diagnostics market share based on product and Service, type of test, technology and application.
Report Includes
- Analyses of the global market trends, with historic market revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Estimation of the actual market size and revenue forecast for the global CDx market in USD million values, and corresponding market share analysis by product and service, technology, application, type of test, and region
- Identification of the viable technology drivers and barriers through a holistic review of various platform technologies and their potential applications in the development of new CDx products
- Discussion of feasible market opportunities for companion diagnostics products via identification of high-growth applications in different therapeutic areas, with a focus on the biggest and fastest-expanding markets for diseases
- Updated information on recent market developments and clinical trials, as well as the leading companies engaged in research and development (R&D) and products in the companion diagnostics reagent pipeline with SWOT analyses
- Review of the patents and patent applications on companion diagnostics and deep dive of recent patent publications related to CDx products and technologies
- Insight into the recent industry structure of companion diagnostics, competitive aspects of each product segments, increasing investment on R&D activities, market growth strategies, and company revenue share analysis
- Descriptive company profiles of the leading global players, including Abbott Laboratories, Bio-Rad Laboratories Inc., Illumina Inc., Foundation Medicine Inc., Myriad Genetics Inc., F. Hoffmann-La Roche Ltd., Qiagen N.V., and Thermo Fisher Scientific Inc.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 286 |
| Forecast Period | 2022 - 2027 |
| Estimated Market Value (USD) in 2022 | $6.4 Billion |
| Forecasted Market Value (USD) by 2027 | $13 Billion |
| Compound Annual Growth Rate | 15.3% |
| Regions Covered | Global |
Company Profiles
- Abbott
- Adaptive Biotechnologies Corp.
- Agilent Technologies Inc.
- Amoy Diagnostics Co. Ltd.
- Almac Group Ltd.
- Arup Laboratories
- Autogenomics Inc. (Acquired by Prescient Medicine)
- Biocartis
- Biodesix Inc.
- Biofluidica
- Biomerieux Sa
- Bio-Techne
- Cerba Research
- Circulogene
- Danaher
- Diasorin S.P.A.
- Exact Sciences Corp.
- F. Hoffmann-La Roche Ltd.
- Guardant Health Inc.
- Hologic Inc.
- Icon plc
- Illumina Inc.
- Invivoscribe Inc.
- Maze Therapeutics
- Myriad Genetics Inc.
- Neogenomics Laboratories
- Qiagen
- Quest Diagnostics Inc.
- Resonance Health Ltd.
- Siemens Healthineers AG
- Spartan Bioscience Inc.
- Sysmex Corp.
- Thermo Fisher Scientific Inc.
- Trimgen Corp.
- Vela Diagnostics Inc.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
2.1 Highlights of the Market for Companion Diagnostics (Cdx)
Chapter 3 Market and Technology Background
3.1 Introduction
3.2 Personalized Medicine and Biomarkers
3.2.1 Predictive Biomarkers
3.3 Companion Diagnostics and Complementary Diagnostics
3.3.1 Companion Diagnostics Development
3.3.2 Cdx Stakeholders
3.3.3 Technologies Used in Cdx
3.3.4 Applications of Cdx
3.3.5 Regulatory Aspects of Cdx
Chapter 4 Global Market for Companion Diagnostics by Product and Service
4.1 Market Overview
4.2 Market Share and Forecast
4.2.1 Instruments
4.2.2 Consumables
4.2.3 Services
Chapter 5 Global Market for Companion Diagnostics by Type of Test
5.1 Market Overview
5.2 Market Share and Forecast
5.2.1 Ldt-Cdx
5.2.2 Commercial Cdx
Chapter 6 Global Market for Companion Diagnostics by Technology
6.1 Market Overview
6.2 Market Share and Forecast
6.2.1 Immunohistochemistry
6.2.2 in Situ Hybridization
6.2.3 Polymerase Chain Reaction
6.2.4 Next-Generation Sequencing
6.2.5 Genotyping
6.2.6 Others
6.2.7 Services
Chapter 7 Global Market for Companion Diagnostics by Application
7.1 Market Overview
7.2 Market Share and Forecast
7.2.1 Cancer
7.2.2 Market for the Application of Cdx in Cancer by Type
7.2.3 Neurologic Disorders
7.2.4 Cardiovascular Disease
7.2.5 Infectious Disease
7.2.6 Other Diseases
Chapter 8 Global Market for Companion Diagnostics by Region
8.1 North America
8.1.1 U.S.
8.1.2 Canada
8.2 Europe
8.2.1 Germany
8.2.2 U.K.
8.2.3 France
8.2.4 Italy
8.2.5 Rest of Europe
8.3 Asia-Pacific
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 Rest of Asia-Pacific
8.4 Rest of the World
Chapter 9 Industry Structure
9.1 Overview
9.2 Stakeholders in Companion Diagnostics
9.3 Driving Trends in Companion Diagnostics
9.4 Business Models of Companion Diagnostics
9.5 Grants and Funding in Companion Diagnostics
9.6 Collaborations and Partnerships
9.7 Mergers and Acquisitions
9.7.1 Market Share Analysis
9.8 Leading Market Players in Companion Diagnostics Market, by Technology
9.8.1 Leading Market Players in Ihc Market
9.8.2 Leading Market Players in Ish Market
9.8.3 Leading Market Players in Pcr Market
9.8.4 Leading Market Players in Ngs Market
9.8.5 Leading Market Players in Genotyping Market
9.8.6 Leading Market Players in Others (Tropism, Mri) Cdx Market
Chapter 10 Patent Review
10.1 Introduction
10.2 Patents on Companion Diagnostics Market
10.3 Patent Analysis
10.3.1 Patents by Year
10.3.2 Patents by Top Applicant
10.3.3 Patents by Top Owner
10.3.4 Patents by Jurisdiction
Chapter 11 Clinical Trials Analysis
11.1 Introduction
11.2 Clinical Trials and Cdx
11.3 Clinical Trials Analysis
11.3.1 Clinical Trials Analysis, by Type of Study
11.3.2 Clinical Trials Analysis, by Status
11.3.3 Clinical Trials Analysis, by Phase
11.3.4 Clinical Trials Analysis, by Region
11.3.5 Clinical Trials Analysis, by Application
11.3.6 Companies With Companion Diagnostics in Clinical Trials
Chapter 12 Analysis of Market Opportunities
12.1 Introduction
12.2 Market Dynamics
12.2.1 Strengths
12.2.2 Challenges
12.2.3 Opportunities
12.2.4 Threats
12.3 Impact of the Covid-19 Pandemic
For more information about this report visit https://www.researchandmarkets.com/r/h9tgys
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
